SI-BONE (SIBN) Statistics

SI-BONE Inc (SIBN) is a medical device company that develops and commercializes products for the treatment of patients with musculoskeletal disorders. The company's main product is the iFuse Implant System, which is used in minimally invasive surgical procedures for sacroiliac joint fusion. The iFuse Implant System is designed to stabilize the sacroiliac joint and provide long-lasting relief from pain and dysfunction. SI-BONE Inc's stock statistics indicate that the company has a market capitalization of $1.5 billion and a current share price of $61.20. The stock has a 52-week range of $24.55 to $87.07 and a P/E ratio of 57.01.

When it comes to valuation metrics, SI-BONE Inc has a price-to-sales ratio of 10.80 and a price-to-book ratio of 25.84. These metrics suggest that the stock may be trading at a premium compared to its industry peers. In terms of fundamentals, SI-BONE Inc reported a total revenue of $162.44 million in the most recent fiscal year, translating to a revenue per share of $5.40. The company's enterprise value-to-EBITDA ratio is 78.69, indicating that it may be slightly overvalued. SI-BONE Inc also has a profit margin of -5.37%, which suggests that the company is currently operating at a loss. Additionally, the company has a total debt of $13.25 million and a gross profit of $121.18 million, demonstrating its financial stability.